glp-1 drugs fda approved medicare part d coverage 2025 Majesta Big policy shift in obesity
Description
doi:10.1016/j.oret.2024.12.006 25
Current research does not confirm safety
Wysham C, Blevins T, Arakaki R, et al
doi: 10.3389/fendo.2021.721135 [DOI] [PMC free article] [PubMed] [Google Scholar] 59.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al
East Asia: In East Asia, China and Japan are experiencing strong demand for GLP-1 receptor agonists, driven by an increasing prevalence of type 2 diabetes and expanding access to diabetes treatments
